XWARICE
Market cap14mUSD
Dec 23, Last price
7.49PLN
1D
-2.73%
1Q
-26.57%
IPO
-24.34%
Name
Medinice SA
Chart & Performance
P/E
—
P/S
255.07
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.90%
Rev. gr., 5y
189.32%
Revenues
225k
-8.54%
Net income
-5m
L-2.57%
CFO
-3m
L+23.64%
Profile
Medinice S.A. provides medical solution for cardiology and cardiac surgery. The company support scientists for product commercialization including prototyping, clinical trials and certification, and product sales. Medinice S.A. was founded in 2012 and is based in Warsaw, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 225 -8.54% | 246 -14.58% | 288 -22.58% | |||||
Cost of revenue | 225 | 196 | 1,514 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 50 | (1,226) | ||||||
NOPBT Margin | 20.33% | |||||||
Operating Taxes | 281 | 10 | ||||||
Tax Rate | 562.00% | |||||||
NOPAT | (231) | (1,236) | ||||||
Net income | (5,072) -2.57% | (5,206) 82.09% | (2,859) -9.44% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 1,096 | 8 | 25,837 | |||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 160 | 206 | 388 | |||||
Long-term debt | 852 | 664 | 544 | |||||
Deferred revenue | 2,813 | 3,467 | 7,162 | |||||
Other long-term liabilities | ||||||||
Net debt | (15,453) | (25,275) | (36,218) | |||||
| Cash flow | ||||||||
Cash from operating activities | (3,447) | (2,788) | (1,682) | |||||
CAPEX | (6,474) | (3,516) | (4,353) | |||||
Cash from investing activities | (6,727) | (4,116) | (6,663) | |||||
Cash from financing activities | (691) | (3,852) | 28,730 | |||||
FCF | (13) | (374) | (85) | |||||
| Balance | ||||||||
Cash | 10,324 | 21,186 | 31,997 | |||||
Long term investments | 6,141 | 4,959 | 5,153 | |||||
Excess cash | 16,454 | 26,133 | 37,136 | |||||
Stockholders' equity | (14,254) | (10,293) | (6,841) | |||||
Invested Capital | 50,751 | 51,355 | 55,222 | |||||
ROIC | ||||||||
ROCE | 0.12% | |||||||
| EV | ||||||||
Common stock shares outstanding | 6,396 | 6,428 | 5,764 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 358 | 364 | (864) | |||||
EV/EBITDA | ||||||||
Interest | 62 | 60 | 43 | |||||
Interest/NOPBT | 120.00% | |||||||